Home LiteratureArticle Details
PMID: 20620663 Published · ppublish English Comparative Study Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline.

Neurobiology of aging ·Vol. 31 ·No. 8 ·2010-08-00 ·Pages 1386-400

Chou YY, Leporé N, Saharan P, Madsen SK, Hua X, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM, Alzheimer's Disease Neuroimaging Initiative

Abstract

Ideal biomarkers of Alzheimer's disease (AD) should correlate with accepted measures of pathology in the cerebrospinal fluid (CSF); they should also correlate with, or predict, future clinical decline, and should be readily measured in hundreds to thousands of subjects. Here we explored the utility of automated 3D maps of the lateral ventricles as a possible biomarker of AD. We used our multi-atlas fluid image alignment (MAFIA) method, to compute ventricular models automatically, without user intervention, from 804 brain MRI scans with 184 AD, 391 mild cognitive impairment (MCI), and 229 healthy elderly controls (446 men, 338 women; age: 75.50 +/- 6.81 [SD] years). Radial expansion of the ventricles, computed pointwise, was strongly correlated with current cognition, depression ratings, Hachinski Ischemic scores, language scores, and with future clinical decline after controlling for any effects of age, gender, and educational level. In statistical maps ranked by effect sizes, ventricular differences were highly correlated with CSF measures of Abeta(1-42), and correlated with ApoE4 genotype. These statistical maps are highly automated, and offer a promising biomarker of AD for large-scale studies.

MeSH Terms
Aged Aged, 80 and over Alzheimer Disease/cerebrospinal fluid,pathology,psychology Amyloid beta-Peptides/cerebrospinal fluid Biomarkers/cerebrospinal fluid Brain Mapping/methods Cerebral Ventricles/pathology Cognition Disorders/cerebrospinal fluid,pathology,psychology Cohort Studies Female Humans Longitudinal Studies Magnetic Resonance Imaging/methods Male Peptide Fragments/cerebrospinal fluid Pilot Projects Prospective Studies tau Proteins/cerebrospinal fluid
Chemicals
Amyloid beta-Peptides Biomarkers Peptide Fragments amyloid beta-protein (1-42) tau Proteins
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Chou Yi-Yu
Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Los Angeles, CA, USA.
Leporé Natasha
Saharan Priyanka
Madsen Sarah K
Hua Xue
Jack Clifford R
Shaw Leslie M
Trojanowski John Q
Weiner Michael W
Toga Arthur W
Thompson Paul M
Alzheimer's Disease Neuroimaging Initiative
References (56)
56 references, click to expand
  1. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition.
    Neuroimage. 2009 Apr 15;45(3):645-55 PMID: 19280686
  2. Obesity is linked with lower brain volume in 700 AD and MCI patients.
    Neurobiol Aging. 2010 Aug;31(8):1326-39 PMID: 20570405
  3. Multivariate tensor-based morphometry on surfaces: application to mapping ventricular abnormalities in HIV/AIDS.
    Neuroimage. 2010 Feb 1;49(3):2141-57 PMID: 19900560
  4. Expanding ventricles may detect preclinical Alzheimer disease.
    Neurology. 2008 Mar 11;70(11):824-5 PMID: 18332339
  5. High-resolution random mesh algorithms for creating a probabilistic 3D surface atlas of the human brain.
    Neuroimage. 1996 Feb;3(1):19-34 PMID: 9345472
  6. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry.
    Neuroimage. 2008 May 15;41(1):19-34 PMID: 18378167
  7. Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia.
    Neuroimage. 2004;23 Suppl 1:S2-18 PMID: 15501091
  8. CSF markers for incipient Alzheimer's disease.
    Lancet Neurol. 2003 Oct;2(10):605-13 PMID: 14505582
  9. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.
    Neuroimage. 2008 Nov 15;43(3):458-69 PMID: 18691658
  10. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
    J Psychiatr Res. 1975 Nov;12(3):189-98 PMID: 1202204
  11. Trajectories of brain loss in aging and the development of cognitive impairment.
    Neurology. 2008 Mar 11;70(11):828-33 PMID: 18046010
  12. Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer's disease.
    Neuroimage. 2008 Apr 1;40(2):615-630 PMID: 18222096
  13. Changes in premorbid brain volume predict Alzheimer's disease pathology.
    Neurology. 2003 Aug 26;61(4):487-92 PMID: 12939422
  14. Disease classification with hippocampal shape invariants.
    Hippocampus. 2009 Jun;19(6):572-8 PMID: 19437498
  15. Ventricular volume and dementia progression in the Cardiovascular Health Study.
    Neurobiol Aging. 2007 Mar;28(3):389-97 PMID: 16504345
  16. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls.
    Neuroimage. 2008 Oct 15;43(1):59-68 PMID: 18675918
  17. The clinical use of structural MRI in Alzheimer disease.
    Nat Rev Neurol. 2010 Feb;6(2):67-77 PMID: 20139996
  18. Brain structure and obesity.
    Hum Brain Mapp. 2010 Mar;31(3):353-64 PMID: 19662657
  19. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.
    Lancet. 2001 Jul 21;358(9277):201-5 PMID: 11476837
  20. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study.
    Neurology. 2008 Sep 2;71(10):743-9 PMID: 18765650
  21. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Ann Neurol. 2009 Apr;65(4):403-13 PMID: 19296504
  22. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.
    Hum Brain Mapp. 2009 Sep;30(9):2766-88 PMID: 19172649
  23. Predicting the rate of cognitive decline in aging and early Alzheimer disease.
    Neurology. 2004 Jul 13;63(1):108-14 PMID: 15249619
  24. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Alzheimers Dement. 2005 Jul;1(1):55-66 PMID: 17476317
  25. Inferring brain variability from diffeomorphic deformations of currents: an integrative approach.
    Med Image Anal. 2008 Oct;12(5):626-37 PMID: 18658005
  26. Mapping hippocampal and ventricular change in Alzheimer disease.
    Neuroimage. 2004 Aug;22(4):1754-66 PMID: 15275931
  27. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  28. Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors.
    Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4872-7 PMID: 15772166
  29. Continuous medial representation of brain structures using the biharmonic PDE.
    Neuroimage. 2009 Mar;45(1 Suppl):S99-110 PMID: 19059348
  30. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.
    Arch Neurol. 2003 Oct;60(10):1385-9 PMID: 14568808
  31. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
    J Magn Reson Imaging. 2008 Apr;27(4):685-91 PMID: 18302232
  32. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.
    AJNR Am J Neuroradiol. 2010 Feb;31(2):347-54 PMID: 20075088
  33. Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease.
    Neuroimage. 2010 Jun;51(2):542-54 PMID: 20197096
  34. The topography of grey matter involvement in early and late onset Alzheimer's disease.
    Brain. 2007 Mar;130(Pt 3):720-30 PMID: 17293358
  35. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space.
    J Comput Assist Tomogr. 1994 Mar-Apr;18(2):192-205 PMID: 8126267
  36. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study.
    Hypertension. 1992 Sep;20(3):340-8 PMID: 1516953
  37. Alzheimer's disease: genes, proteins, and therapy.
    Physiol Rev. 2001 Apr;81(2):741-66 PMID: 11274343
  38. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly.
    Proc Natl Acad Sci U S A. 2010 May 4;107(18):8404-9 PMID: 20404173
  39. Detection, visualization and animation of abnormal anatomic structure with a deformable probabilistic brain atlas based on random vector field transformations.
    Med Image Anal. 1997 Sep;1(4):271-94 PMID: 9873911
  40. Development and validation of a geriatric depression screening scale: a preliminary report.
    J Psychiatr Res. 1982-1983;17(1):37-49 PMID: 7183759
  41. Dynamics of gray matter loss in Alzheimer's disease.
    J Neurosci. 2003 Feb 1;23(3):994-1005 PMID: 12574429
  42. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Brain. 2009 May;132(Pt 5):1355-65 PMID: 19339253
  43. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  44. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
    Lancet Neurol. 2010 Jan;9(1):119-28 PMID: 20083042
  45. Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry.
    Hum Brain Mapp. 2010 Apr;31(4):499-514 PMID: 19780044
  46. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.
    Curr Alzheimer Res. 2009 Aug;6(4):347-61 PMID: 19689234
  47. Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.
    Neuroimage. 2010 May 15;51(1):63-75 PMID: 20139010
  48. In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease.
    J Neurol. 2009 Jun;256(6):916-24 PMID: 19252794
  49. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
    Neurology. 2004 Feb 24;62(4):591-600 PMID: 14981176
  50. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects.
    Neuroimage. 2009 Dec;48(4):668-81 PMID: 19615450
  51. The Clinical Dementia Rating (CDR): current version and scoring rules.
    Neurology. 1993 Nov;43(11):2412-4 PMID: 8232972
  52. Boosting power for clinical trials using classifiers based on multiple biomarkers.
    Neurobiol Aging. 2010 Aug;31(8):1429-42 PMID: 20541286
  53. Unfolding the human hippocampus with high resolution structural and functional MRI.
    Anat Rec. 2001 Apr;265(2):111-20 PMID: 11323773
  54. Three-dimensional mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: gender effects.
    Biol Psychiatry. 2001 Jul 15;50(2):84-97 PMID: 11526999
  55. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
    Neurology. 2008 Jan 15;70(3):191-9 PMID: 18195264
  56. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
    Ann Neurol. 1995 Oct;38(4):643-8 PMID: 7574461
Article Info
Journal
Neurobiology of aging
Abbr.
Neurobiol Aging
ISSN
1558-1497
DOI
10.1016/j.neurobiolaging.2010.05.001
Published
2010-08-00
Pages
1386-400
Language
English
Region
United States
NLM ID
8100437
PMCID
PMC2904619
Subset
IM
Grants
NIA NIH HHS · K01 AG030514 · United States
NIA NIH HHS · U01 AG024904-04 · United States
NIA NIH HHS · P30 AG010129-19 · United States
NIA NIH HHS · U01 AG024904-06 · United States
NIA NIH HHS · P30 AG010129 · United States
NIA NIH HHS · K01 AG030514-02 · United States
NIA NIH HHS · K01 AG030514-04 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · U19 AG010483 · United States
External Links
PubMed source DOI: 10.1016/j.neurobiolaging.2010.05.001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2